

CONTENTS

Inauguration

Messages from DR H. FRANK	3
PROFESSOR DR DR HANS-ACHIM MÜLLER	4
DR K. ZEITLER	5
Tribute to Professor Dr E. Freerksen and Dr H. Wheate. H. COUNT BALLESTREM	6
Reply from PROFESSOR DR E. FREERKSEN	
Keynote address. DR K. FLEISCHER	7
Abstracts	11

Session I. Clinical Aspects. Chairman: D. L. Leiker

1 The Malta experience.—Isoprodian rifampicin combination treatment for leprosy. G. DEPASQUALE	29
2 On the epidemiology of leprosy in Malta. D. L. LEIKER	38
3 First assessment of the Malta Leprosy Eradication Project. D. L. LEIKER	42
4 A report on two follow-up investigations of the Malta-Project, 1983 and 1986. W. H. JOPLING	47
5 Report of the Joint Leprosy/Tuberculosis Project in Paraguay. A. E. ALVARENGA	53
6 Comparison of DDS with two combined chemotherapy regimens for multibacillary leprosy. Results after 3 years of treatment. A prospective randomized multicentre study. M. DIETRICH and R. WABITSCH	60
7 The impact of multidrug therapy implementation in the Tanzania National TB Leprosy Programme. H. J. CHUM	63
8 Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. J. M. MEHTA, I. S. GANDHI, S. B. SANE and M. N. WAMBURKAR	67
9 Some clinical impressions of multidrug therapy in leprosy. J. M. MEHTA	75
10 Experience with MDT in Sierra Leone: clinical, operational and managerial analysis. M. RANGARAJ and J. RANGARAJ	77
11 Clinical problems in the initiation and assessment of multidrug therapy. M. F. R. WATERS, D. S. RIDLEY and MARIAN J. RIDLEY	92
12 Preliminary evaluation of the effect of WHO-MDT on disabilities in leprosy patients in Malawi, Central Africa. G. BOERRIGTER and J. M. PÖNNIGHAUS	101
13 The use of MDT in the three Western Regions of Nepal. P. G. KALTHOFF	106
14 Operational aspects of the implementation of multidrug therapy at ALERT, Ethiopia. M. BECX-BLEUMINK	115
15 Combined chemotherapy of multibacillary leprosy of 6 months' duration. N. ONSUN, T. SAYLAN and S. R. PATTYN	124
16 The future of leprosy in the Dominican Republic: experience with MDT. D. MARTINEZ CRUZ	127

Session II. Test Models for the Effective Control of Chemotherapy Free Communication. Chairman:

A. M. Dhople

17 The use of rodent models in assessing antimicrobial activity against <i>Mycobacterium leprae</i> . R. H. GELBER	137
18 Limited <i>in vitro</i> multiplication of <i>Mycobacterium leprae</i> : application to screening potential antileprosy compounds. A. M. DOHPLE and KARA J. GREEN	149
19 Single bacterial cell mass analysis: a rapid test method in leprosy therapy control. U. SEYDEL and B. LINDNER	163
20 Metabolism in <i>Mycobacterium leprae</i> : possible targets for drug action. P. R. WHEELER	171
21 Host-pathogen interaction—new <i>in vitro</i> drug test systems against <i>Mycobacterium leprae</i> —possibilities and limitations. P. R. MAHADEWAN, R. JAGANNATHAN, A. BHAGARIA, S. VEJARE and S. AGARWAL	182
22 Isolation of environment-derived <i>Mycobacterium leprae</i> from soil in Bombay. J. KAZDA, R. GANAPATI, C. REVANKAR, T. M. BUCHANAN, D. B. YOUNG and L. M. IRGENS	201
23 Investigations into the cultivation of <i>Mycobacterium leprae</i> . A multifactorial approach. L. KATO	209

Session III. Developments and Future Aspects. Chairman: Enno Freerksen

24 Recent developments in the field of multidrug therapy and future research in chemotherapy of leprosy. J. H. GROSSET	223
25 Strategies in the development of new drugs and drug combinations against leprosy, demonstrated on the example of folate and gyrase inhibitors. J. K. SEYDEL, M. ROSENFELD, M. SATHISH, M. WIESE, K.-J. SCHAPER, G. HACHTEL, R. HALLER, M. KANSY and A. M. DHOPLE	235
26 Development of inhibitors of mycobacterial ribonucleotide reductase. K.-J. SCHAPER, J. K. SEYDEL, M. ROSENFELD and J. KAZDA	254
27 Efficacy of different regimens in multibacillary leprosy. S. R. PATTYN	265
28 Preliminary results of treatment of leprosy patients in the Netherlands with daily rifampicin, dapsone and clofazimine D. L. LEIKER	272

Final Bulletin D. L. LEIKER, A. M. DHOPLE and E. FREERKSEN	274
---	-----

Addendum

Multidrug therapy cost: a hypothetical analysis. C. R. REVANKAR	279
Discussions	286
Address list of participants	286